Skip to content

Pilot Study : FreeStyle Libre Pro Flash Continuous Glucose Monitoring System in Subjects With Diabetes on HemoDIALsis

FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System in Subjects With Diabetes on HemoDIALsis (FSL-DIAL Pilot Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04641650
Acronym
FSL DIAL
Enrollment
29
Registered
2020-11-24
Start date
2021-07-21
Completion date
2022-11-09
Last updated
2024-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Kidney Failure

Keywords

glycemia, diabetes, kidney failure, dialysis, glucose sensor

Brief summary

Continuous monitoring of glucose with a FreeStyle Libre pro sensor in diabetic and dialysis patients

Interventions

None listed

Sponsors

Centre Hospitalier Saint Joseph Saint Luc de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diabetes without any change in treatment in the last 3 months * Hemodialysis for \> 3 months * Recent laboratory HbA1c (\< 15 days)

Exclusion criteria

* Patient does not show non-opposition * Skin allergy to the sensor * Sepsis / Acute anaemia

Design outcomes

Primary

MeasureTime frameDescription
Difference between estimated Hba1c (or Glucose Management Index (GMI)) with FreeStyle Libre Pro sensor and laboratory Hba1cAt sensor removal (day 14)Comparison between estimated HbA1c with 14 days of CGM data and laboratory HbA1c (routine blood test in hemodialysis) in each subject

Secondary

MeasureTime frameDescription
Time in glucose rangeAt sensor removal (day 14)Percent (%) time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to ≤10 mmol/L), obtained using professional continuous glucose monitoring (CGM)
Time with Glucose < 70mg/dLAt sensor removal (day 14)% time with glucose \<70 mg/dL
Time with Glucose > 180 mg/dLAt sensor removal (day 14)% time with glucose \>180 mg/dL
Glucose total coefficient of variation (CV)At sensor removal (day 14)Glucose total CV (%)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026